A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This research study is investigating a new medication called Trontinemab for individuals in the early stages of Alzheimer's disease. This includes people experiencing mild memory and thinking problems that are due to Alzheimer's, or those with early Alzheimer's dementia. The main goal is to find out if Trontinemab is effective at improving or stabilising these symptoms, and importantly, if it is safe for patients. To do this, some participants will receive Trontinemab, while others will receive a placebo, which looks like the active drug but has no medicine in it. Researchers will carefully compare the results from both groups to understand the potential of this new treatment for Alzheimer's disease.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is focused on a new potential treatment for Alzheimer's disease called Trontinemab. Alzheimer's is a condition that affects memory, thinking, and daily activities. This particular study is for people who are in the early stages – meaning they might have mild memory issues due to Alzheimer's (often called mild cognitive impairment) or mild Alzheimer's dementia.
The main aim of the research is to see if Trontinemab can help with the symptoms of early Alzheimer's and if it is safe to use. Researchers are comparing Trontinemab to a 'placebo', which is an inactive substance that looks just like the real medication. This comparison helps them understand if any changes seen in participants are truly due to Trontinemab or other factors.
Finding new, safe, and effective treatments for Alzheimer's disease is incredibly important. Studies like this help medical professionals learn more about the illness and develop better ways to support people living with it. Your involvement could contribute significantly to our understanding and potential future treatments.
النقاط الرئيسية
- The study investigates a new drug, Trontinemab, for early Alzheimer's disease.
- It aims to check if Trontinemab is safe and effective in slowing down Alzheimer's symptoms.
- Participants will receive either Trontinemab or an inactive placebo.
- A 'study partner' is required to support participants during the trial.
- Careful assessments, including brain scans and memory tests, will be part of the study.
- يمكنك الانسحاب من الدراسة في أي وقت دون التأثير على رعايتك الطبية.
من قد يكون مؤهلاً؟
To join this study, you would generally need to be between 50 and 90 years old and have been diagnosed with early Alzheimer's disease, or be experiencing mild memory problems thought to be due to Alzheimer's.
Researchers will need to confirm that changes in your brain are indeed linked to Alzheimer's, often through special scans. You'll also need to have someone, like a family member or close friend, who can act as a 'study partner' to help you throughout the study. Your memory and thinking abilities will be assessed to make sure you fit the study's specific criteria.
Not everyone can join, even if they have early Alzheimer's. For example, if you have other significant medical conditions that aren't well controlled, or if previous brain issues like a stroke or serious head injury could interfere with the study's results, you might not be suitable. A research doctor will carefully review your health to ensure the study is safe and appropriate for you.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Are you between 50 and 90 years old?
- Do you have early Alzheimer's disease or mild memory difficulties likely due to Alzheimer's?
- Do you have a family member or close friend who could be your 'study partner'?
- Are you generally in good health apart from your Alzheimer's diagnosis?
- Have you had brain scans that show evidence of Alzheimer's-related changes?
ماذا يتضمن المشاركة؟
If you decide to take part, you would receive either Trontinemab or a placebo. This would involve regular visits to the study clinic for check-ups, assessments of your memory and thinking, and scans like MRI to look at your brain. You might also have blood tests and spinal fluid tests (if appropriate and agreed upon) to help understand the disease and the treatment's effects. Your study partner would need to be available to attend some appointments with you and provide information about your memory and daily life. The exact number of visits and the total duration aren't specified here, but clinical trials usually involve a commitment over several months to a few years, with careful follow-up throughout.
المخاطر والفوائد المحتملة
Locations (142)
- جامعة ألاباما في برمنغهامالرمز البريدي المؤكدبرمنغهام، الولايات المتحدة
- Banner Sun Health Research Instituteالرمز البريدي المؤكدمدينة الشمس، الولايات المتحدة
- Irvine Center for Clinical Researchالرمز البريدي المؤكدإرفاين، الولايات المتحدة
- Inglewood Clinicalsالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- UCSF - Memory and Aging Centerالرمز البريدي المؤكدسان فرانسيسكو، الولايات المتحدة
- Syrentis Clinical Researchالرمز البريدي المؤكدسانتا آنا، الولايات المتحدة
- K2 Medical Research - The Villagesالرمز البريدي المؤكدLady Lake, United States
- K2 Medical Research, LLCالرمز البريدي المؤكدمايتلاند، الولايات المتحدة
- Renstar Medical Researchالرمز البريدي المؤكدأوكالا، الولايات المتحدة
- Axiom Brain Health LLCالرمز البريدي المؤكدتامبا، الولايات المتحدة
- Charter Research - Lady Lake/The Villagesالرمز البريدي المؤكدالقرى، الولايات المتحدة
- Alzheimer?s Research and Treatment Centerالرمز البريدي المؤكدWellington, United States
أسئلة شائعة
What is Trontinemab?
Trontinemab is an investigational medication being studied to see if it can help people with early Alzheimer's disease.
ما هو الدواء الوهمي؟
A placebo is a substance that looks exactly like the study medication but does not contain any active drug. It helps researchers compare the effects of the new treatment.
What does 'early symptomatic Alzheimer's disease' mean?
It refers to the beginning stages of Alzheimer's, where symptoms like memory or thinking problems are noticeable, ranging from mild cognitive impairment to mild dementia caused by Alzheimer's.
Who is a 'study partner'?
A study partner is typically a trusted family member or close friend who knows you well and can help you with study appointments and provide information about your health and daily life.
Will I know if I'm getting Trontinemab or the placebo?
In most studies, participants (and often the doctors) don't know who is receiving the active drug versus the placebo. This helps ensure unbiased results.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.